Official announcements
Search narrowed by
Recall
|
Medicines
|
23/12/2010
The marketing authorization holder has received increased adverse reactions (aseptic peritonitis) to the above batch. Therefore, Baxter Healthcare has decided to recall this batch from those dialysis centers that were supplied with this product.
Recall
|
Medicines
|
21/12/2010
The marketing authorization holder informed its supplied customers in a fax transmission on December 20, 2010, that due to complaints on the German market regarding the unpleasant odor of the tablets, a recall would also be carried out in Austria as…
Recall
|
Medicines
|
15/12/2010
The distribution partner Croma-Pharma has informed the supplied customers by letter dated December 9, 2010, that the above mentioned batches have to be recalled due to reduced stability. The affected batches show a negative trend or Out of…
Replacement
|
Medicines
|
13/12/2010
The marketing authorization holder informed its supplied customers in a letter dated December 13, 2010, that the affected batch exhibited significant deviations in disintegration time and friability.
Recall
|
Medicines
|
29/11/2010
The marketing authorization holder informed its supplied customers by letters dated October 29 and November 25, 2010, that the sterility of the products cannot be guaranteed for the batches listed above.
Replacement
|
Medicines
|
18/11/2010
The marketing authorization holder has informed its supplied customers by letter dated 18.11.2010 that due to 5 complaints about visible particles after reconstitution of the product, which occurred in two batches of this medicinal speciality, the…
Recall
|
Medicines
|
17/11/2010
Ebewe/Sandox has initiated a voluntary recall of certain lots of ebetraxate as a precautionary measure. See related file.
Recall
|
Medicines
|
17/10/2010
Ebewe/Santoz has initiated a voluntary recall of certain lots of 5-fluorouracil as a precautionary measure. See related file.
Medicines
|
28/09/2010
Notice of supply difficulties for PegIntron Powder and Solvent for Solution for Injection. See related file.
Recall
|
Medicines
|
29/09/2008
The following quality defect has been identified in the drug product Ionsys (Fentanyl) 40 microgram per dose iontophoretic transdermal system: A defect in the IONSYS systems may potentially cause the system to self-activate. See related files.